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Aim. To assess the prevalence of diabetic foot and other associated conditions in patients with diabetes mellitus under renal
replacement in the region of Lleida, Spain.Methods. This was an observational, cross-sectional study of 92 dialysis-treated diabetic
patients. Besides a podiatric examination, we explored the presence of cardiovascular risk factors, late diabetes complications,
including peripheral neuropathy, atherosclerotic disease, and peripheral artery disease. We assessed risk factors for foot ulceration
and amputation by logistic regression. Results. Prevalent diabetic foot was found in 17.4% of patients, foot deformities were found
in 54.3%, previous ulcer was found in 19.6%, and amputations were found in 16.3%; and 87% of them had some risk of suffering
diabetic foot in the future. We observed a high prevalence of patients with peripheral neuropathy and peripheral artery disease
(89.1% and 64.2%, resp.). Multivariable analysis identified diabetic retinopathy and advanced atherosclerotic disease (stenosing
carotid plaques) as independent risk factors for foot ulceration (𝑝 = 0.004 and 𝑝 = 0.023, resp.) and diabetic retinopathy also
as an independent risk factor for lower-limb amputations (𝑝 = 0.013). Moreover, there was a temporal association between the
initiation of dialysis and the incidence of amputations. Conclusion. Diabetic patients receiving dialysis therapy are at high risk of
foot complications and should receive appropriate and intensive foot care.
1. Introduction
Diabetic foot (DF) is a chronic complication of diabetesmelli-
tus (DM) associated with a high economic and social burden.
The lifetime risk of developing a foot ulcer in a patient with
diabetes ranges from 15% to 25% [1, 2]. The development
of a DF ulcer depends on a constellation of several factors
occurring together, and several causal pathways can lead to
ulceration [3]. One of these pathways is the triad neuropathy-
foot deformity-minor trauma [4].There are important factors
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that determine the ulcer outcome, such as peripheral arterial
disease (PAD), infection, and patient-related factors, includ-
ing advanced age and the presence of comorbidities that can
affect wound healing or renal replacement therapy [3, 5].
Diabetic nephropathy has been identified as an impor-
tant risk factor for foot ulceration and amputation [6, 7].
Additionally, dialysis treatment has been reported as an inde-
pendent risk factor in diabetic patients with chronic kidney
disease [8]. About 20%of diabetic patients develop foot ulcers
during the first year after initiation of dialysis [9], and the
amputation rate is 4% for every year in dialysis therapy [10].
Moreover, renal failure has been reported to independently
predict the risk of nonhealing ischaemic and neuroischaemic
foot lesions and major amputations [11, 12]. Uraemia has a
negative effect on ulcer healing, with nonuraemic patients
having a 2.45 increased probability of primary healing of the
ulcer [12]. Additionally, end-stage renal disease (ESRD) has a
stronger negative effect in diabetic patients with PAD than in
those without this complication [11].
The aim of the study was to assess the prevalence of DF
and other associated conditions in patients with DM under
renal replacement in the region of Lleida, Spain.
2. Methods
2.1. Design. This was an observational, cross-sectional study
conducted between November 2010 and March 2011. All
diabetic patients with chronic kidney disease who were
receiving replacement therapy (haemodialysis and peritoneal
dialysis) from the two existing dialysis centres in the health
area of Lleida, a region of Spain with a population around
450,000, were included.
2.2. Studied Variables. Study participants were recruited
from the only two haemodialysis centres in the area of Lleida,
Spain, and those under peritoneal dialysis during their rou-
tine clinical visits at the Nephrology Unit of the Hospital
Arnau de Vilanova. Patients were considered to have DM if
they had ever been diagnosed with the disease or, alterna-
tively, if they were receiving any antidiabetic agent. The type
of DMwas assigned based on theirmedical records or clinical
data when the diagnosis was missing.
For each participant, data were collected on the following
variables: age; gender; type and duration of DM; type and
duration of dialysis (i.e., haemodialysis or peritoneal dialysis);
presence of cardiovascular risk factors: hypertension, that is,
if they had ever been diagnosed with the disease or were
receiving any antihypertensive medication; smoking status
and dyslipidaemia; and long-termdiabetes complications: the
presence of any degree of diabetic retinopathy [DR], amauro-
sis, neuropathy, cerebrovascular disease, and ischaemic heart
disease. Moreover, during anamnesis, patients were asked
about their previous history of foot ulcers, defined according
to the current consensus of the InternationalWorking Group
on the Diabetic Foot (IWGDF) [13].
All patients underwent a detailed foot examination to
identify previous lower-limb amputations (minor or major)
and foot deformities. Foot deformity was defined according
to the IWGDF recommendations [14], namely, as structural
abnormalities of the foot such as hammer toes, mallet
toes, claw-toes, hallux valgus, prominent metatarsal heads,
residuals of neuroosteoarthropathy, amputations, or other
foot surgeries. Peripheral neuropathy (PN) was explored with
an ultrabiothesiometer (Me. Te. Da. Srl., IT) applied on the
dorsal part of the first toe and considered abnormal when
the patient needed >25V intensity to perceive the vibration.
PAD was explored through the ankle-brachial index (ABI),
assessed with an ES100XMiniDop Surgical Doppler (Koven
Technology, US). ABI values were classified as normal (from
0.91 to 1.30), moderate ischaemia (from 0.41 to 0.90), severe
ischaemia (from 0 to 0.40), and noncompressible because of
the presence of calcification (>1.30). Moreover, in patients
with an ABI value >1.30, we also explored the pedal or
posterior tibial pulse: if any of the pulses was nonpalpable,
the patient was classified as having PAD. Finally, a carotid
ultrasound was performed using a GE Vivid and BT09
Doppler (General Electric, US) in order to detect subclinical
atherosclerosis through morphological examination (i.e., the
presence or absence of plaques in any of the territories of the
carotid artery) and to calculate the intima-media thickness
(IMT) of the common carotid artery. A detailed description
of the procedure has been recently published [15]. Briefly, B-
mode images of the left and right segments of the common
carotid artery were recorded and electronically stored; IMT
measurements were performed offline using semiautomatic
software with the last (previous to the bulb) centimetres of
the common carotid artery, and the mean IMT was obtained
by averaging the right- and left-side values.
Based on the ABI and on the reference values for carotid
IMT in a Spanish community cohort [16], atherosclerotic dis-
ease was classified as follows: AD0, no atherosclerotic disease:
ABI > 0.9 and <1.3 and IMT < 90% of the reference interval
(RI) for sex and age; AD1, ABI 0.7–0.9 or = 1.3 and/or IMT >
90% of the RI for sex and age; AD2, nonstenotic plaques
(<50% lumen stenosis); AD3, ABI < 0.7 or >1.3 and/or
stenotic plaques with >50% lumen stenosis.
Patients were classified into four risk groups based on the
presence of risk factors according to the IWGDF consensus
[13]: (a) group 0: patients without distal sensory neuropathy;
(b) group 1: patients with distal sensory neuropathy; (c)
group 2: neuropathic patients with some grade of PAD and/or
foot deformity; and (d) group 3: neuropathic patients with a
history of prior foot ulcer or lower-limb amputation.
The local Ethics Committee from the Hospital Arnau
de Vilanova (Lleida, Spain) approved the protocol, and all
patients signed a written informed consent form prior to
participation. The study was conducted in accordance with
the Declaration of Helsinki (1964).
2.3. Statistical Analysis. Baseline variables were described by
range, mean and standard deviation (±SD) for quantitative
variables, or frequency and percentage for qualitative vari-
ables. A bivariate analysis was conducted to assess the risk
of ulceration and amputation through contingency tables;
the significance was assessed with Pearson’s Chi-square test
and the estimated relative risk and corresponding 95% con-
fidence intervals (CIs) were calculated using exact methods
(mid-p) and normal approximation (Wald). For quantitative
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variables, we estimated the mean differences and assessed the
significance by performing Student’s 𝑡-test (for normally dis-
tributed variables) or Mann-Whitney test (for non-normally
distributed variables). In addition, amultivariate analysis was
conducted to evaluate the association of the variables with
amputation and prognosis value. For this purpose, we used
simple logistic regressionmodels adjusted for all the variables
that were observed to be individually statistically significantly
associated with ulcers or amputations in the bivariate analysis
at a 𝑝 value < 0.1. Subsequently, we applied a backwards-
stepwise regression algorithm to select the most relevant
factors, using Akaike’s Information Criterion.
Finally, we studied whether there was a temporal asso-
ciation between the onset of dialysis and amputations. For
this, we calculated the absolute and relative frequency (%) for
the punctual and cumulative incidence (from the time of first
amputation and from the onset of dialysis). Negative values
indicate patientswith amputations prior to the start of dialysis
treatment.
All statistical analyses were performed using the comput-
ing environment R (RDevelopment Core Team, 2005) setting
the significance level to 0.05.
3. Results
BetweenNovember 2010 andMarch 2011, a total of 92 (35.8%)
patients out of the 257 who were receiving renal replacement
treatment were identified as having a diagnosis of DM.
Demographic and clinical characteristics of the sample are
shown in Table 1. The mean age was 70.9 years (SD = 12.1
years), and the percentage of males was 62%, and all were of
Caucasian origin. Eighty-one patients had type 2 DM (88%)
and the mean diabetes duration was 22.3 years (SD = 12.2
years). The vast majority of patients were on haemodialysis
(92.4%), and the mean duration of dialysis treatment was 4.8
years (SD = 4.3 years).
Concerning cardiovascular risk factors (Table 1), we ob-
served that 43.5% of patients were current or former smokers,
68.5% of them had dyslipidaemia, and 84.8% of them had
hypertension. In relation to late diabetic complications, DR
was present in 62%; out of the 71 patients who underwent
retinopathy exploration, 12% of them had amaurosis; and
9.8% and 22.8% had stroke and coronary heart disease,
respectively.
The carotid ultrasound and PAD examinations were
conducted in 81 patients. The mean IMT value was 0.90 cm
(±0.17), and all patients had some grade of atheromatous dis-
ease, with 92.5% of them having nonstenotic carotid plaques.
The prevalence of foot complications (Table 1) was, from the
highest to the lowest, PN (89.1%), moderate or severe PAD
(64.2%), foot deformities (54.3%), previous ulcer (19.6%), DF
(17.4%), and amputations (16.3%) (Table 1). Finally, based on
the IWGDF classification, out of 83 patients explored, 87%
had some risk grade for suffering DF in the future.
From the bivariate analysis, the risk of ulceration was
significantly increased in patients with DR (𝑝 = 0.0006)
(Table 2) and was also increased in patients with stenosing
carotid plaques (𝑝 = 0.05) and in patients with a previous
stroke (𝑝 = 0.049). The risk of amputation was significantly
Table 1: Demographic and clinical characteristics of patients
included in the study.
Variable Patients(𝑁 = 92)
Age (years), mean (SD) 70.9 (12.1)
Male sex, 𝑛 (%) 57 (62)
Type 2 diabetes, 𝑛 (%) 81 (88)
Diabetes duration (years), mean (SD) 22.3 (12.2)
Haemodialysis 85 (92.4)
Duration of dialysis (years), mean (SD) 4.8 (4.3)
Cardiovascular risk factors and long-term diabetes
complications, 𝑛 (%)
Smoking status (current and former) 40 (43.5)
Dyslipidaemia 63 (68.5)
Hypertension 78 (84.8)
Retinopathy∗ 57 (62.0)
Amaurosis∗ 11 (12.0)
Stroke 9 (9.8)
Coronary heart disease 21 (22.8)
Foot complications, 𝑛 (%)
Peripheral neuropathy† 82 (89.1)
Peripheral artery disease‡ 52 (64.2)
Foot deformities 50 (54.3)
Previous ulcer 18 (19.6)
Current ulcer: diabetic foot 16 (17.4)
Patients with amputations 15 (16.3)
Risk for diabetic foot (IWGDF), 𝑛 (%)
Risk 0 3 (3.3)
Risk 1 18 (19.6)
Risk 2 32 (34.8)
Risk 3 30 (32.6)
Not classified 7 (7.6)
∗Data available for 71 patients; †data available for 90 patients; ‡data available
for 81 patients.
SD, standard deviation.
increased in patients with DR (𝑝 = 0.02) and in patients with
stenosing carotid plaques (𝑝 = 0.03) (Table 3). Furthermore,
the multivariate analysis showed that foot ulceration was
independently related to DR and stenosing carotid plaques
(𝑝 = 0.004 and 𝑝 = 0.023, resp.) and that DR was also
an independent risk factor for lower-limb amputation (𝑝 =
0.013).
Finally, for those patients with an amputation, the
relationship between the start of dialysis therapy and the
cumulative incidence of amputations was assessed (Figure 1).
The incidence increased progressively with time, showing an
accumulated incidence of 18.7%, 37.5%, 43.8%, and 50% in the
first, second, third, and fourth years after initiating dialysis,
respectively.
4. Discussion
In this cross-sectional study in a representative population
from our region, we observed that diabetic patients undergo-
ing dialysis therapy had a high prevalence of DR, underlying
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Table 2: Bivariate and multivariate analysis for risk factors associated with foot ulceration.
Risk factor Foot ulceration Bivariate analysis Multivariate analysis
Yes No RR/mean diff. (95% CI) 𝑝 value Adjusted 𝑝 value
Gender, 𝑛 (%)
Male 21 (36.8) 37 (63.2) 1.84 (0.87–3.87) 0.09 0.60
Female 7 (20.0) 28 (80.0)
Age (years), mean (SD) 70.1 (12.6) 71.3 (11.9) −1.15 (−6.81–4.49) 0.75
Diabetes, 𝑛 (%)
Type 1 4 (36.4) 7 (63.6) 1.22 (0.52–2.87) 0.65
Type 2 24 (29.6) 57 (70.4)
Diabetes duration (years), mean (SD) 23.4 (11.0) 21.8 (12.8) 1.66 (−3.58–6.90) 0.43
Dialysis duration, mean (SD) 4.9 (4.7) 4.7 (4.1) 0.15 (−1.91–2.22) 0.93
Current or former smoker, 𝑛 (%)
Yes 14 (35) 26 (65.0) 1.3 (0.70–2.40) 0.41
No 14 (27.0) 38 (73.1)
Dyslipidaemia, 𝑛 (%)
Yes 19 (30.2) 44 (69.8) 0.97 (0.50–1.88) 0.92
No 9 (31.0) 38 (73.1)
Hypertension, 𝑛 (%)
Yes 25 (32.1) 53 (68.0) 1.49 (0.52–4.29) 0.45
No 3 (21.4) 11 (78.6)
Retinopathy, 𝑛 (%)
Yes 26 (45.6) 31 (54.4) 6.84 (ne) 0.0006 0.004
No 0 (0.0) 14 (100)
Amaurosis, 𝑛 (%)
Yes 3 (27.3) 8 (72.7) 0.72 (0.26–2.00) 0.54
No 23 (37.7) 38 (62.3)
Stroke, 𝑛 (%)
Yes 6 (60.0) 4 (40.0) 2.23 (1.20–4.15) 0.04 0.73
No 22 (26.8) 38 (62.3)
IHD, 𝑛 (%)
Yes 10 (47.6) 11 (52.4) 1.87 (1.03–3.42) 0.06 0.93
No 18 (25.4) 53 (74.6)
PN
Yes 25 (30.5) 57 (69.5) 2.43 (0.37–15.70) 0.32
No 1 (12.5) 7 (87.5)
PAD, 𝑛 (%)
Yes 15 (29.4) 36 (70.6) 1.41 (0.58–3.43) 0.45
No 5 (20.8) 19 (79.2)
Foot deformities, 𝑛 (%)
Yes 14 (28.0) 36 (72.0) 0.84 (0.45–1.55) 0.58
No 14 (33.3) 38 (66.7)
AD, 𝑛 (%)
AD3 12 (34.3) 23 (65.7) 1.43 (0.71–2.85) 0.31
AD1 or AD2 11 (23.9) 35 (76.1)
Carotid plaques, 𝑛 (%)
Stenosing 4 (66.7) 2 (33.3) 1.43 (0.71–2.85) 0.05 0.013
Nonstenosing 18 (23.9) 35 (76.1)
IMT, cm, mean (SD) 0.9 (0.2) 0.9 (0.2) 0.05 (−0.05–0.16) 0.4
AD, atheromatous disease; IHD, ischaemic heart disease; IMT, intima-media thickness; ne, nonestimable; PAD, peripheral artery disease; PN, peripheral
neuropathy; RR, risk ratio.
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Table 3: Bivariate and multivariate analysis for risk factors associated with lower-limb amputations.
Risk factor Amputations Bivariate analysis Multivariate analysis
Yes No RR/mean diff. (95% CI) 𝑝 value Adjusted 𝑝 value
Gender, 𝑛 (%)
Male 10 (17.5) 47 (82.5) 1.22 (0.45–3.29) 0.70
Female 5 (14.3) 30 (85.7)
Age (years), mean (SD) 72.3 (10.3) 70.6 (12.4) 1.69 (−4.50–7.89) 0.74
Diabetes, 𝑛 (%)
Type 1 1.0 (9.0) 10 (90.9) 0.52 (0.07–3.61) 0.78
Type 2 14 (17.3) 67 (82.7)
Diabetes duration (years), mean (SD) 23.9 (13.6) 22.0 (12.0) 1.90 (−6.00–9.81) 0.79
Dialysis duration, mean (SD) 5.5 (5.9) 4.6 (3.9) 0.81 (−2.55–4.18) 0.92
Current or former smoker, 𝑛 (%)
Yes 6 (15) 34 (85) 0.86 (0.33–2.23) 0.78
No 9 (17.3) 43 (82.7)
Dyslipidaemia, 𝑛 (%)
Yes 10 (15.9) 53 (84.1) 0.92 (0.34–2.45) 0.85
No 5 (17.2) 43 (82.8)
Hypertension, 𝑛 (%)
Yes 14 (18.0) 64 (82.1) 2.51 (0.35–17.61) 0.35
No 1 (7.14) 13 (92.9)
Retinopathy, 𝑛 (%)
Yes 15 (26.3) 42 (73.7) 3.94 (ne) 0.02 0.023
No 0 (0.0) 14 (100.0)
Amaurosis, 𝑛 (%)
Yes 2 (18.8) 9 (81.8) 0.85 (0.22–3.26) 0.86
No 13 (12.3) 48 (78.7)
Stroke, 𝑛 (%)
Yes 2 (20.0) 8 (80.0) 1.26 (0.33–4.79) 0.71
No 13 (15.9) 69 (84.1)
IHD, 𝑛 (%)
Yes 4 (19.1) 17 (81.0) 1.21 (0.43–3.46) 0.69
No 11 (15.5) 60 (84.5)
PN
Yes 15 (8.3) 67 (81.7) 1.64 (ne) 0.21
No 0 (0.0) 8 (100.0)
PAD, 𝑛 (%)
Yes 9 (17.7) 42 (83.4) 1.47 (0.34–6.29) 0.31
No 2 (8.3) 22 (91.7)
Foot deformities, 𝑛 (%)
Yes 6 (12.0) 44 (88.0) 0.51 0.24
No 9 (21.4) 33 (78.6)
AD, 𝑛 (%)
AD3 7 (20.0) 28 (80.0) 1.84 (0.63–5.31) 0.27
AD1 or AD2 5 (10.9) 41 (89.1)
Carotid plaques, 𝑛 (%)
Stenosing 3 (50.0) 3 (50) 4.62 (1.64–13) 0.03 0.12
Nonstenosing 8 (10.8) 66 (89.2)
IMT, mean (SD) 0.9 (0.2) 0.9 (0.2) 0.009 (−0.11–0.13) 0.97
AD, atheromatous disease; IHD, ischaemic heart disease; IMT, intima-media thickness; ne, nonestimable; PAD, peripheral artery disease; PN, peripheral
neuropathy; RR, risk ratio.
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Figure 1: Cumulative incidence (%) of amputations depending
on the time from initiating dialysis (years). All patients with an
amputation were evaluated, including those who started dialysis
after an amputation (with a negative number of years).
PN, PAD, and foot deformities.Moreover, important vascular
complications of diabetes, such as DR and stenosing carotid
plaques, were shown to be independently associated with the
risk of foot ulcers and lower-limb amputations.
The prevalence of PN in our sample was 89.1%, which is
higher than the prevalence reported in some previous studies,
ranging between 37% and 57% [8, 17, 18], but closer to oth-
er studies, with a prevalence between 77.2% and 80% [11, 19].
This higher prevalence could be due to the use of an ultra-
biothesiometer, which is a precise and sensitive quantitative
method, and differences between studies could be explained
by disparities in the way the neurological assessment was
performed and the instrument used, that is, loss of pressure
sensation using a 10 g monofilament or vibration perception
threshold with a neurothesiometer. However, even studies
using the same instrument report wide differences: 3 of the
studies using a monofilament reported a prevalence of 37%
[18], 49% [17], and>77% [11] and 3 studies using a neurothesi-
ometer reported a PN prevalence of 46% [18], 56.8% [8], and
80% [19]. Differencesmay be therefore due to unstandardised
methodologies for assessment, for example, examiner experi-
ence, number and sites in the foot used, plantar or dorsal side
of the foot, or definition of the pathological outcome.
The prevalence of PAD in our study (64.2%) is higher
than the 45% reported by Jones et al. [18] and lower than
the 73.5% reported by Kaminski et al. [17]. In the case of
Jones et al., the study only explored 21 patients, and only 11 of
them were diabetic; and in the Kaminski et al. study, vascular
insufficiency was determined by manual palpation of both
pedal pulses, and not by Doppler ultrasound.
The prevalence of foot deformities in our study (54.3%)
was much lower than the prevalence described in two previ-
ous studies, which found a prevalence between 79% [18] and
71.4% [17], but higher than the 22% reported in another
study [8]. The high association of foot lesions with advanced
diabetic nephropathy may be explained by the long duration
of diabetes, which predisposes to both nephropathy and foot
lesions, and by the particularly high risk for nephropathic
patients to develop macroangiopathic or neuropathic com-
plications or a combination of both.
The frequency of current foot ulcer in our studywas 17.4%,
which is higher than the frequency reported in some studies
(4%–12%) [17–19] and close to the figure described in another
study comparing dialysis versus non-dialysis-treated patients
(21% versus 4%) [8]. Moreover, the percentage of patients
who had at least one episode of ulceration (i.e., current or
previous) was similar to the one reported by Jones et al. (32%)
[18]. Finally, the rate of amputations in this study (16.2%)
was also in line with the 18% reported in another study [19]
and again reported to be much higher than that in diabetic
patients without dialysis (6.4%) [8].
According to the IWGDF risk scale, 87% of our patients
had one or more risk factors for developing DF, which is very
similar to the 89.8% described by Kaminski et al. [17], who
found that the figure was lower in control groups (80% in
DM patients and 71.8% in DM patients with end-stage renal
disease). Our result is also close to the 93% and 96% risks
reported by another group [8, 19].
The results of the multivariate analysis showed that the
risk of foot ulceration was independently associated with DR
and the presence of stenosing carotid plaques and that ampu-
tations were also independently associated with DR. The
prevalence ofDR among type 2DMpatients in haemodialysis
has been previously reported to be between 70% and 79%
[8, 20], which is only slightly higher than the 63% observed
in our study. This is in line with the results of a retrospective
study where the incidence of retinopathy was found to be
significantly higher among subjects in haemodialysis who
had a foot ulcer than that among those who did not (88%
versus 54%) [21] and also with a recent meta-analysis that
identified retinopathy as a risk factor for foot ulceration
in adults with ESRD treated with dialysis [22]. Moreover,
an association between DR and increased IMT as an early
atherosclerosis marker in diabetic patients has been reported
in two cross-sectional studies [15, 23]. Actually, diabetes is
one of the most frequent and the most important clinical
situationswhere endothelial dysfunction occurs [24].The fact
that we did not identify PN as a risk factor for ulceration
and amputation could be explained by its high prevalence
in our population (89.1%), acting as a confounding variable
because PN is also correlated with the progression of chronic
kidney disease and secondary to uraemia [6]. Conversely,
DR is not confounded by uraemia and may be more specific
and better reflect generalised microangiopathy than PN or
diabetic nephropathy.
Finally, the pattern of cumulative incidence of amputa-
tions after the initiation of dialysis therapy in our cohort
is similar to the one described by Game et al. [9], with an
increasing incidence as treatment is prolonged in time. This
could be explained by the combination of a progression of
micro- and macrovascular complications while on dialysis
and risk factors related to the progression of chronic kidney
disease (e.g., malnutrition and chronic inflammation) and to
dialysis therapy itself, which is an independent risk factor for
major foot amputations irrespective of the presence of DM
[25].
In our study, we did not find a relationship between
foot ulceration and PAD. Although two previous studies
have identified PAD as an independent risk factor for foot
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ulceration in patients with chronic kidney disease [26, 27],
another study conducted in diabetic patients could not dem-
onstrate this association [28]. However, none of these studies
assessed differences among patients in dialysis. Indeed, our
results are in agreement with another study reporting that
PAD was not an independent risk factor after adjustment for
dialysis therapy [8], although the same group had previously
reported that it was independently associated in a multiracial
sample [19]. The authors considered that the sample pop-
ulation and the inclusion of interrelated PAD and dialysis
variables could explain the discrepancy of results between the
two studies.
Foot deformities have been shown to increase plantar
peak pressure and are considered as a factor for developing
foot ulcers [14, 29]. However, and in linewith a previous study
reporting that foot deformities were less prevalent among
patients in dialysis compared with no dialysis treatment
[8], we could not find a direct relationship between foot
deformities and foot ulceration or lower-limb amputations.
Some of the most frequent reasons for the appearance of
ulcers are frictions and repeated shoe-induced microtrauma,
which can be largely prevented by the use of appropriate
therapeutic footwear. In our catchment area, this type of
footwear is reimbursed for patientswhohave one ormore risk
factors for ulceration, and it is often examined and prescribed
at diabetic foot units. It is then possible that patients with
foot deformities were already wearing adequate protective
footwear, thus decreasing the chance of finding a relationship
with foot ulcers and/or amputations.
The present study has strengths and limitations that must
be acknowledged. The main strength of the study is that it is,
as far as we are aware, the first one assessing the relationship
between DF and atherosclerotic disease using the presence of
atheromatous plaques by carotid artery ultrasound in diabetic
patients receiving dialysis. Additionally, this is the first study
published so far from a Spanish population. One limitation
of the study is the relatively small sample size (92 patients),
although it is representative of the area, encompassing the
entire dialysis population of Lleida (Spain). Moreover, almost
all patients were receiving haemodialysis, which prevented
comparison with patients managed with peritoneal dialysis
(𝑛 = 7) or even a separate analysis for each group. In addition,
during PAD assessment, we did not quantitatively evaluate
stenosis because the equipment we used did not record
ultrasoundwaveforms, andwe cannot discard thatABI values
were in the normal range in patients with both arterial
stiffness and stenosis, thus potentially underestimating the
prevalence of PAD in our sample. Finally, not all patients were
explored for all studied outcomes, which could have led in
some cases to an underestimation of the true prevalence.
5. Conclusions
In our region, diabetic patients in dialysis treatment had a
high prevalence of DF, and most of them had one or more
risk factors for developing an ulcer in the future. DR and
atheromatous disease were directly related to the appearance
of ulcers and amputations.
Although this was not an interventional study, we believe
that our findings have direct implications on foot care
delivery, since there is a temporal association between the
initiation of dialysis and the incidence of amputations. We
suggest that all such patients should be considered at high
risk and that appropriate foot care including preventive
measures (e.g., scheduled foot examinations and education)
and therapeutic intervention should be a must for all diabetic
subjects in or initiating dialysis.
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